Impact of a Personalized Medication Plan on Duration of Treatment With Potent Opioids in Acute Non-cancer Musculoskeletal Pain.

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Clinical Phase

NA

Total Enrollment

200 participants

Study Classification

INTERVENTIONAL

Study Start Date

2024-01-18

Study Completion Date

2028-07-18

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The aim of this study is to evaluate whether patients who benefit from a personalized pharmaceutical plan (PPP) during their hospitalization, allowing them to be informed and sensitized, are treated for a shorter period of time with strong opioids with a reduced risk of dependence compared to a management according to the usual modalities in the rheumatology services concerned.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Usual Care Intervention Research Evaluating the Impact of a Personalized Pharmaceutical Plan on the Duration of Opioid Treatment in Non-cancerous Pain

NCT05196386

Non-cancerous Pain Opioid Use

COMPLETED NA

Comparison of Standard Opioid Prescription Versus Prescription Guided by Pharmacogenetic Analysis in Patients With Non-cancerous Chronic Pain.

NCT03498014

Non-cancerous Chronic Pain

WITHDRAWN NA

Analgesic Self-medication for Acute Pain by Patients Awaiting a Consultation With a General Practitioner

NCT05412407

Acute Pain

UNKNOWN NA

Antagonistic Interaction CB1-paracetamol

NCT00750347

Pain

COMPLETED PHASE1

Dependence on Analgesics in Chronic Non-cancer Pain

NCT03346408

Pain, Chronic

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Acute Pathology of the Locomotor System

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

OTHER

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

interventional group

benefiting from a multi-professional intervention around the strong opioid treatment with the aim of setting up a personalized pharmaceutical plan

Group Type EXPERIMENTAL

personalized pharmaceutical plan

Intervention Type OTHER

multi-professional intervention around strong opioid treatment with targeted pharmaceutical interview

control group

routine management, including medication reconciliation at entry and exit and pharmaceutical analysis of prescriptions

Group Type NO_INTERVENTION

No interventions assigned to this group

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

personalized pharmaceutical plan

multi-professional intervention around strong opioid treatment with targeted pharmaceutical interview

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patient hospitalized in the rheumatology department
* Patient with acute pain in the context of a non-cancerous, non-traumatic, high-energy musculoskeletal pathology
* Patient for whom a prescription of strong opioid derivatives is initiated in rheumatology or patient for whom a prescription of strong opioid derivatives is maintained in rheumatology if the initial prescription has a maximum duration of 30 consecutive days prior to inclusion

Exclusion Criteria

* Patient with cancer or fibromyalgia already diagnosed at inclusion
* Patient with poor French language skills
* Taking a strong opioid treatment for more than 30 consecutive days prior to inclusion
* Person judged by the prescriber or pharmacist as not autonomous for the management of strong opioid treatment
* Patient already included in the study

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No